Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S.

EBioMedicine. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

2.

Regulation of IRE1 RNase activity by the Ribonuclease inhibitor 1 (RNH1).

Tavernier Q, Bennana E, Poindessous V, Schaeffer C, Rampoldi L, Pietrancosta N, Pallet N.

Cell Cycle. 2018;17(15):1901-1916. doi: 10.1080/15384101.2018.1506655. Epub 2018 Sep 5.

3.

A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Petitgas C, Ceballos-Picot I, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Sci Rep. 2017 Sep 5;7(1):10550. doi: 10.1038/s41598-017-10338-6.

4.

6-mercaptopurine promotes energetic failure in proliferating T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Oncotarget. 2017 Jun 27;8(26):43048-43060. doi: 10.18632/oncotarget.17889.

5.

The effect of immunosuppressive molecules on T-cell metabolic reprogramming.

Fernández-Ramos AA, Poindessous V, Marchetti-Laurent C, Pallet N, Loriot MA.

Biochimie. 2016 Aug;127:23-36. doi: 10.1016/j.biochi.2016.04.016. Epub 2016 Apr 25. Review.

PMID:
27126071
6.

A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney.

Mami I, Tavernier Q, Bouvier N, Aboukamis R, Desbuissons G, Rabant M, Poindessous V, Laurent-Puig P, Beaune P, Tharaux PL, Thervet E, Chevet E, Anglicheau D, Pallet N.

J Am Soc Nephrol. 2016 Sep;27(9):2670-83. doi: 10.1681/ASN.2015060703. Epub 2016 Jan 28.

8.

Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.

Petitprez A, Poindessous V, Ouaret D, Regairaz M, Bastian G, Guérin E, Escargueil AE, Larsen AK.

Int J Oncol. 2013 May;42(5):1644-53. doi: 10.3892/ijo.2013.1868. Epub 2013 Mar 27.

PMID:
23546019
9.

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Mégalophonos VF, Kamsu-Kom N, Petitprez A, Escargueil AE, Boudou P, Dumont S, Cervera P, Fléjou JF, André T, Tournigand C, Chibaudel B, de Gramont A, Larsen AK.

Clin Cancer Res. 2011 Oct 15;17(20):6522-30. doi: 10.1158/1078-0432.CCR-11-1607. Epub 2011 Aug 31.

10.

Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.

Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, Galmarini CM, Henriques JA, Escargueil AE, Larsen AK.

Mol Cancer Ther. 2011 Aug;10(8):1481-9. doi: 10.1158/1535-7163.MCT-11-0252. Epub 2011 May 27.

11.

The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators.

Rocca CJ, Poindessous V, Soares DG, Ouadrani KE, Sarasin A, Guérin E, de Gramont A, Henriques JA, Escargueil AE, Larsen AK.

Biochem Pharmacol. 2010 Aug 1;80(3):335-43. doi: 10.1016/j.bcp.2010.04.012. Epub 2010 Apr 22.

PMID:
20399198
12.

Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells.

Escargueil AE, Poindessous V, Soares DG, Sarasin A, Cook PR, Larsen AK.

J Cell Sci. 2008 Apr 15;121(Pt 8):1275-83. doi: 10.1242/jcs.023259.

13.

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13062-7. Epub 2007 Jul 26.

14.

Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1.

Léonce S, Kraus-Berthier L, Golsteyn RM, David-Cordonnier MH, Tardy C, Lansiaux A, Poindessous V, Larsen AK, Pierré A.

Cancer Res. 2006 Jul 15;66(14):7203-10.

15.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9. Epub 2005 Aug 2.

PMID:
16075278
16.

Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.

Koeppel F, Poindessous V, Lazar V, Raymond E, Sarasin A, Larsen AK.

Clin Cancer Res. 2004 Aug 15;10(16):5604-13.

17.

The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties.

Lemke K, Poindessous V, Skladanowski A, Larsen AK.

Mol Pharmacol. 2004 Oct;66(4):1035-42. Epub 2004 Jul 16.

PMID:
15258255
18.

Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.

Poindessous V, Koeppel F, Raymond E, Cvitkovic E, Waters SJ, Larsen AK.

Int J Oncol. 2003 Nov;23(5):1347-55.

PMID:
14532976
19.

Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.

Poindessous V, Koeppel F, Raymond E, Comisso M, Waters SJ, Larsen AK.

Clin Cancer Res. 2003 Jul;9(7):2817-25.

Supplemental Content

Loading ...
Support Center